Rus Biopharm

PSK Pharma (part of Rus Biopharm Group) is a fully integrated bio-pharmaceutical company. The manufacturing units are located in Dubna. In small molecules business, company has dedicated facility for manufacturing most of its Active Pharmaceutical Ingredients. These APIs are further used to make formulations in seven different forms of formulations. In biotech, company has one of the best product portfolio in the country, with 5 biotech products already in the market and 13 more at various stages of registration. The company has a state of art formulation unit, and a Drug Substance unit will be ready by January 2024, making it fully integrated biotech manufacturer. PSK Pharma is undisputed leader in Asthma and COPD segment in Russia, having 17 inhalation products in its portfolio. The company has launched 12 «first generics» in Russia and would continue to launch the first generics in Russia for the products that are termed as «complex generics». Apart from inhalation segment, PSK Pharma manufacturers products for treatment of Oncology, Auto-immune disorders, HIV, TB, GI and CNS. Since 2017, PSK Pharma has invested 5 Billion Rubles in its development. Another 7 Billion Rubles would be invested in expansion from 2023 till end 2025.